University of British ColumbiaVancouver, BC, Canada
64 - Persistent Improvement in Dysphagia Symptoms for 52 Weeks Following a Single Administration of EP-104GI in RESOLVE, an Ongoing Phase 1b/2 Trial in Eosinophilic Esophagitis (Late-Breaking Abstract)
Wednesday, October 29, 202510:00 AM - 10:10 AM PDT